Akebia Therapeutics, Inc. (AKBA) vs Nautilus Biotechnolgy, Inc. (NAUT)
A side-by-side comparison of Akebia Therapeutics, Inc. and Nautilus Biotechnolgy, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AKBA
Akebia Therapeutics, Inc.
$0.90HealthcareDelayed quote: Oct 6, 2026, 12:10 PM EDT
NAUT
Nautilus Biotechnolgy, Inc.
$1.92HealthcareDelayed quote: Oct 6, 2026, 12:10 PM EDT
Total return — AKBA vs NAUT
growth of $100 · dividends reinvested · last 6yAKBA -91.7% (-34.0%/yr)NAUT -82.1% (-24.9%/yr)NAUT compounded faster over this window
AKBA NAUT
AKBA vs NAUT: by the numbers
- •NAUT is the larger company ($244M vs $240M market cap).
- •Both run net losses; AKBA's is the smaller (-13.54% vs -29747.89% net margin).
Metrics side by side
Valuation
| Metric | AKBA | NAUT |
|---|---|---|
| P/S ratio | 1.10 | 1285.95 |
| P/B ratio | 9.60 | 1.86 |
| FCF yield | 16.73% | N/A |
Profitability
| Metric | AKBA | NAUT |
|---|---|---|
| Gross margin | 79.48% | 0.00% |
| Operating margin | 9.95% | 0.00% |
| Net margin | -13.54% | -29747.89% |
| ROE | -118.58% | -43.11% |
| ROIC | -7.08% | -40.52% |
Growth (annualized)
| Metric | AKBA | NAUT |
|---|---|---|
| Revenue CAGR (5Y) | -0.26% | N/A |
| Total return CAGR (5Y) | -20.07% | -20.56% |
Frequently asked
- How have AKBA and NAUT total returns compared?
- Over the past 5 years, AKBA delivered -20.07% and NAUT delivered -20.56% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Akebia Therapeutics ROENautilus Biotechnolgy ROEAkebia Therapeutics operating marginNautilus Biotechnolgy operating marginAkebia Therapeutics revenue growthNautilus Biotechnolgy revenue growthAkebia Therapeutics free cash flowNautilus Biotechnolgy free cash flow
Akebia Therapeutics & Nautilus Biotechnolgy appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.